MissionOur mission is to engage, excite, and educate as many people as possible, particularly young people, about biotechnology and its immense potential to heal the sick, feed the hungry, restore the environment, and fuel the economy.We promote excellence in biotechnology research from the best and brightest minds in the next generation of innovators.
Filter News
Found 644,625 articles
- Biotechnology is technology that utilizes biological systems, living organisms or parts of this to develop or create different products. Brewing and baking bread are examples of processes that fall within the concept of biotechnology (use of yeast (= living organism) to produce the desired product).
- Unit: Biotechnology. Intro to biotechnology. Intro to biotechnology (Opens a modal) DNA cloning. DNA cloning and recombinant DNA (Opens a modal) Overview: DNA cloning (Opens a.
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
1/23/2021
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death - - LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials
Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
1/23/2021
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
Lupus Research Alliance Hails Approval of Aurinia's Lupkynis(TM) (voclosporin)
1/23/2021
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month
Meaningful Moment for HIV Treatment as FDA Approves ViiV's Monthly Shot
1/22/2021
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.A Year of COVID-19 Provides Lessons for the Future
1/22/2021
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.A Look at This Week’s Biotech IPOs
1/22/2021
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look.COVID-19 Vaccine Runner-Up Update: Who Will Reach the Finish Line Next?
1/22/2021
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.GSK's Challenging Week: Halted Study, Delayed FDA Decision and Departing Exec
1/22/2021
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.BioSpace Movers & Shakers, Jan. 22
1/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.Pharma Partners Launch Cloud Data-Sharing Initiative
1/22/2021
Ten pharmaceutical companies have joined forces again to launch Accumulus Synergy Inc., a non-profit effort to pool data in the cloud and interact with regulators, in the hopes of speeding the drug approval process.Research Roundup: Blood Test for Severe COVID-19 and More
1/22/2021
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.Seasonal Flu Nearly Eradicated During Pandemic, Despite Rising COVID-19 Cases
1/22/2021
Despite the rising number of COVID-19 cases reported across the globe, rates of influenza have virtually flatlined across the Northern Hemisphere, leading many doctors and researchers to wonder how this could be replicated in non-pandemic times.47% of Americans Still Hesitant to Get COVID-19 Vaccine, New Poll Says
1/22/2021
Americans are still hesitant to be vaccinated against COVID-19, according to just-released research from Invisibly.Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/22/2021
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that effective December 9, 2020, the Company granted nonstatutory stock options for the purchase of up to 1,500 shares of the Companys common stock to one new employee, and nonstatutory stock options for the purchase of up to 35,000 shares of the Companys common stock
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
1/22/2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purcha
FSD Pharma Sets Date for Annual Meeting
1/22/2021
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company”) today announced that it will hold its annual meeting of shareholders (the “Meeting”) on June 29, 2021. The Meeting will address normal course matters, including the presentation of the Company’s audited financial statements, as well as matters contained in a requisition for a special meeting submitted to the Company by certain shareholders of the Compa
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
1/22/2021
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada has committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses.
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
1/22/2021
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies t
Bio-Rad Launches Its Western Blot Learning Center, an Online Multi-media Library of Resources on Immunoblotting
1/22/2021
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the Bio-Rad Western Blotting Learning Center, an online library that provides comprehensive resources, information, and guidance to help researchers improve their experimental western blotting (or immunoblotting) approaches to obtain high-quality data.
XPhyto Provides Comments on Promotional and Marketing Activity
1/22/2021
XPhyto Therapeutics Corp at the request of OTC Markets, is providing the following comments regarding recent promotional activity with respect to the Corporation. The Corporation has been listed on the Canadian Securities Exchange from July 2019.
Biotechnology Stocks
Biotechnology Examples